BRISTOL-MYERS SQUIBB CO (BRM.DE) Fundamental Analysis & Valuation

FRA:BRM • US1101221083

Current stock price

52.09 EUR
+0.89 (+1.74%)
Last:

This BRM.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BRM.DE Profitability Analysis

1.1 Basic Checks

  • BRM had positive earnings in the past year.
  • BRM had a positive operating cash flow in the past year.
  • Of the past 5 years BRM 4 years were profitable.
  • BRM had a positive operating cash flow in each of the past 5 years.
BRM.DE Yearly Net Income VS EBIT VS OCF VS FCFBRM.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B

1.2 Ratios

  • The Return On Assets of BRM (7.83%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of 38.19%, BRM belongs to the top of the industry, outperforming 88.46% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 19.52%, BRM is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for BRM is below the industry average of 17.75%.
  • The last Return On Invested Capital (19.52%) for BRM is above the 3 year average (14.47%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROIC 19.52%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
BRM.DE Yearly ROA, ROE, ROICBRM.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • BRM has a Profit Margin (14.64%) which is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of BRM has grown nicely.
  • BRM has a Operating Margin of 35.82%. This is amongst the best in the industry. BRM outperforms 84.62% of its industry peers.
  • BRM's Operating Margin has improved in the last couple of years.
  • BRM has a Gross Margin of 72.63%. This is comparable to the rest of the industry: BRM outperforms 57.69% of its industry peers.
  • BRM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
BRM.DE Yearly Profit, Operating, Gross MarginsBRM.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

5

2. BRM.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
  • BRM has more shares outstanding than it did 1 year ago.
  • BRM has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BRM has been reduced compared to a year ago.
BRM.DE Yearly Shares OutstandingBRM.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
BRM.DE Yearly Total Debt VS Total AssetsBRM.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • BRM has an Altman-Z score of 2.52. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BRM has a Altman-Z score of 2.52. This is comparable to the rest of the industry: BRM outperforms 44.23% of its industry peers.
  • The Debt to FCF ratio of BRM is 3.51, which is a good value as it means it would take BRM, 3.51 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of BRM (3.51) is better than 63.46% of its industry peers.
  • BRM has a Debt/Equity ratio of 2.33. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 2.33, BRM is not doing good in the industry: 78.85% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Altman-Z 2.52
ROIC/WACC2.27
WACC8.61%
BRM.DE Yearly LT Debt VS Equity VS FCFBRM.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B 50B

2.3 Liquidity

  • A Current Ratio of 1.26 indicates that BRM should not have too much problems paying its short term obligations.
  • BRM has a Current ratio (1.26) which is in line with its industry peers.
  • BRM has a Quick Ratio of 1.14. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
  • BRM's Quick ratio of 1.14 is fine compared to the rest of the industry. BRM outperforms 63.46% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.14
BRM.DE Yearly Current Assets VS Current LiabilitesBRM.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2

3. BRM.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 439.47% over the past year.
  • Measured over the past years, BRM shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.92% on average per year.
  • BRM shows a decrease in Revenue. In the last year, the revenue decreased by -0.22%.
  • Measured over the past years, BRM shows a small growth in Revenue. The Revenue has been growing by 2.54% on average per year.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.15% on average over the next years.
  • BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.54% yearly.
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BRM.DE Yearly Revenue VS EstimatesBRM.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
BRM.DE Yearly EPS VS EstimatesBRM.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

7

4. BRM.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.75, which indicates a very decent valuation of BRM.
  • 90.38% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 24.75. BRM is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 9.47 indicates a reasonable valuation of BRM.
  • BRM's Price/Forward Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 88.46% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.10. BRM is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 9.75
Fwd PE 9.47
BRM.DE Price Earnings VS Forward Price EarningsBRM.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaply inside the industry as 86.54% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, BRM is valued cheaply inside the industry as 92.31% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.51
EV/EBITDA 7.23
BRM.DE Per share dataBRM.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BRM does not grow enough to justify the current Price/Earnings ratio.
  • BRM has a very decent profitability rating, which may justify a higher PE ratio.
  • BRM's earnings are expected to decrease with -4.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)3.28
PEG (5Y)N/A
EPS Next 2Y0.29%
EPS Next 3Y-4.05%

7

5. BRM.DE Dividend Analysis

5.1 Amount

  • BRM has a Yearly Dividend Yield of 4.24%, which is a nice return.
  • BRM's Dividend Yield is rather good when compared to the industry average which is at 1.95. BRM pays more dividend than 82.69% of the companies in the same industry.
  • BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 4.24%

5.2 History

  • The dividend of BRM is nicely growing with an annual growth rate of 6.51%!
Dividend Growth(5Y)6.51%
Div Incr Years3
Div Non Decr Years3
BRM.DE Yearly Dividends per shareBRM.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • 71.52% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
  • BRM's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP71.52%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
BRM.DE Yearly Income VS Free CF VS DividendBRM.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B
BRM.DE Dividend Payout.BRM.DE Dividend Payout, showing the Payout Ratio.BRM.DE Dividend Payout.PayoutRetained Earnings

BRM.DE Fundamentals: All Metrics, Ratios and Statistics

BRISTOL-MYERS SQUIBB CO

FRA:BRM (3/30/2026, 4:49:01 PM)

52.09

+0.89 (+1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners83.3%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap106.08B
Revenue(TTM)48.19B
Net Income(TTM)7.05B
Analysts70.56
Price Target52.4 (0.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.24%
Yearly Dividend2.18
Dividend Growth(5Y)6.51%
DP71.52%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.39%
Min EPS beat(2)6.92%
Max EPS beat(2)11.85%
EPS beat(4)4
Avg EPS beat(4)18.29%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.75%
EPS beat(12)11
Avg EPS beat(12)12.26%
EPS beat(16)15
Avg EPS beat(16)10.82%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.79%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)3.42%
Min Revenue beat(4)0.79%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.86%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)1.77%
PT rev (1m)0%
PT rev (3m)11.1%
EPS NQ rev (1m)0.88%
EPS NQ rev (3m)0.6%
EPS NY rev (1m)4.07%
EPS NY rev (3m)4.48%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)2.94%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)6.81%
Valuation
Industry RankSector Rank
PE 9.75
Fwd PE 9.47
P/S 2.54
P/FCF 9.51
P/OCF 8.63
P/B 6.61
P/tB N/A
EV/EBITDA 7.23
EPS(TTM)5.34
EY10.25%
EPS(NY)5.5
Fwd EY10.56%
FCF(TTM)5.48
FCFY10.51%
OCF(TTM)6.04
OCFY11.59%
SpS20.55
BVpS7.88
TBVpS-9.54
PEG (NY)3.28
PEG (5Y)N/A
Graham Number30.76
Profitability
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROCE 25.91%
ROIC 19.52%
ROICexc 23.22%
ROICexgc 84.94%
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
FCFM 26.65%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
ROICexc(3y)17.24%
ROICexc(5y)15.38%
ROICexgc(3y)72.12%
ROICexgc(5y)85.46%
ROCE(3y)19.19%
ROCE(5y)17.14%
ROICexgc growth 3Y-3.78%
ROICexgc growth 5Y13.73%
ROICexc growth 3Y21.19%
ROICexc growth 5Y33.96%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score7
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Debt/EBITDA 2.03
Cap/Depr 32.69%
Cap/Sales 2.72%
Interest Coverage 8.22
Cash Conversion 66.54%
Profit Quality 182.1%
Current Ratio 1.26
Quick Ratio 1.14
Altman-Z 2.52
F-Score7
WACC8.61%
ROIC/WACC2.27
Cap/Depr(3y)19.36%
Cap/Depr(5y)15.61%
Cap/Sales(3y)2.66%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%
EBIT growth 1Y49.54%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year23.75%
EBIT Next 3Y2.42%
EBIT Next 5Y-1.47%
FCF growth 1Y-7.87%
FCF growth 3Y2.44%
FCF growth 5Y-0.69%
OCF growth 1Y-6.81%
OCF growth 3Y2.71%
OCF growth 5Y0.15%

BRISTOL-MYERS SQUIBB CO / BRM.DE Fundamental Analysis FAQ

What is the fundamental rating for BRM stock?

ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE.


What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.


How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 7 / 10.


What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 2.98% in the next year.


Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?

The dividend rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 7 / 10 and the dividend payout ratio is 71.52%.